Hengeler Mueller advises EQT on acquisition of a minority stake in SHL Medical

13. January 2020

The EQT VIII Fund ("EQT") announced that it has entered into an agreement to acquire a minority stake in SHL Medical ("SHL"). Headquartered in Switzerland, SHL is a world-leading provider of drug delivery solutions such as autoinjectors and serves as a partner to global pharmaceutical companies and biotech firms. The transaction is subject to customary regulatory approvals.

Hengeler Mueller advises EQT on the transaction. The team is led by partners Daniel Möritz and Hans-Jörg Ziegenhain (both M&A) and includes partners Matthias Scheifele (Tax) (all Munich), Nikolaus Vieten (Financing), Christian Hoefs (Employment) (both Frankfurt), Dirk Uwer (Public Law, Düsseldorf) and Markus Röhrig (Antitrust, Brussels), counsel Gunter Wagner (Tax, Munich), Benedikt Migdal, Patrick Wilkening (both IP/IT) and Susanne Koch (Public Law) (all Düsseldorf) as well as associates Johannes Honzen (Frankfurt), Daniel Blagojevic, Hanna Gotta, Florian Dendl, Jimena Janeiro Fong, Christian Lutz (all Munich) (all M&A), Marius Mayer (Employment, Frankfurt) and Anja Balitzki (Antitrust, Düsseldorf).